{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T15:43:12Z","timestamp":1785253392846,"version":"3.55.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim International GmbH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003793","name":"Hj\u00e4rt-Lungfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003793","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004348","name":"Stockholms L\u00e4ns Landsting","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004348","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.diabres.2022.110141","type":"journal-article","created":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T21:52:49Z","timestamp":1667512369000},"page":"110141","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["SOdium-glucose CO-transporter inhibition in patients with newly detected Glucose Abnormalities and a recent Myocardial Infarction (SOCOGAMI)"],"prefix":"10.1016","volume":"193","author":[{"given":"Magnus","family":"Lundin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Ferrannini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Mellbin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Johansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Norhammar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"N\u00e4sman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahira","family":"Shahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stina","family":"Smetana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwin","family":"Venkateshvaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peder","family":"S\u00f6rensson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Ryd\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9324","key":"10.1016\/j.diabres.2022.110141_b0005","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1016\/S0140-6736(02)09089-X","article-title":"Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study","volume":"359","author":"Norhammar","year":"2002","journal-title":"Lancet"},{"issue":"21","key":"10.1016\/j.diabres.2022.110141_b0010","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1016\/j.ehj.2004.07.027","article-title":"The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on diabetes and the heart","volume":"25","author":"Bartnik","year":"2004","journal-title":"Eur Heart J"},{"key":"10.1016\/j.diabres.2022.110141_b0015","doi-asserted-by":"crossref","unstructured":"Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 2020;41(2):255-323.","DOI":"10.1093\/eurheartj\/ehz486"},{"issue":"22","key":"10.1016\/j.diabres.2022.110141_b0020","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1016\/j.ehj.2004.09.021","article-title":"Newly detected abnormal glucose tolerance: an important predictor of long-term outcome after myocardial infarction","volume":"25","author":"Bartnik","year":"2004","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.diabres.2022.110141_b0025","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1177\/1479164114551746","article-title":"Sustained prognostic implications of newly detected glucose abnormalities in patients with acute myocardial infarction: long-term follow-up of the Glucose Tolerance in Patients with Acute Myocardial Infarction cohort","volume":"12","author":"Ritsinger","year":"2015","journal-title":"Diab Vasc Dis Res"},{"issue":"9541","key":"10.1016\/j.diabres.2022.110141_b0030","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/S0140-6736(06)69420-8","article-title":"Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial","volume":"368","author":"Investigators","year":"2006","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.diabres.2022.110141_b0035","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa1203858","article-title":"Basal insulin and cardiovascular and other outcomes in dysglycemia","volume":"367","author":"Investigators","year":"2012","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.diabres.2022.110141_b0040","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.jcjd.2013.06.010","article-title":"Cardiovascular effects of incretins in diabetes","volume":"37","author":"Advani","year":"2013","journal-title":"Can J Diabetes"},{"issue":"5","key":"10.1016\/j.diabres.2022.110141_b0045","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S2213-8587(17)30033-5","article-title":"Integration of recent evidence into management of patients with atherosclerotic cardiovascular disease and type 2 diabetes","volume":"5","author":"Standl","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"16","key":"10.1016\/j.diabres.2022.110141_b0050","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1161\/CIR.0b013e31826e1058","article-title":"Third universal definition of myocardial infarction","volume":"126","author":"Thygesen","year":"2012","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.diabres.2022.110141_b0055","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1089\/dia.2014.0354","article-title":"Accuracy of a simplified glucose measurement device-the HemoCue glucose 201RT","volume":"17","author":"Segerhag","year":"2015","journal-title":"Diabetes Technol Ther"},{"issue":"3","key":"10.1016\/j.diabres.2022.110141_b0060","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1093\/ehjci\/jev014","article-title":"Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"16","author":"Lang","year":"2015","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"1","key":"10.1016\/j.diabres.2022.110141_b0065","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s12968-017-0355-5","article-title":"Myocardial perfusion cardiovascular magnetic resonance: optimized dual sequence and reconstruction for quantification","volume":"19","author":"Kellman","year":"2017","journal-title":"J Cardiovasc Magn Reson"},{"issue":"1","key":"10.1016\/j.diabres.2022.110141_b0070","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/mrm.20110","article-title":"Modified Look-Locker inversion recovery (MOLLI) for high-resolution T1 mapping of the heart","volume":"52","author":"Messroghli","year":"2004","journal-title":"Magn Reson Med"},{"key":"10.1016\/j.diabres.2022.110141_b0075","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1532-429X-16-2","article-title":"T1-mapping in the heart: accuracy and precision","volume":"16","author":"Kellman","year":"2014","journal-title":"J Cardiovasc Magn Reson"},{"key":"10.1016\/j.diabres.2022.110141_b0080","first-page":"63","article-title":"Extracellular volume fraction mapping in the myocardium, part 1: evaluation of an automated method","volume":"14","author":"Kellman","year":"2012","journal-title":"J Cardiovasc Magn Reson"},{"issue":"1","key":"10.1016\/j.diabres.2022.110141_b0085","doi-asserted-by":"crossref","DOI":"10.1186\/s12968-018-0484-5","article-title":"Society for Cardiovascular Magnetic Resonance (SCMR) expert consensus for CMR imaging endpoints in clinical research: part I - analytical validation and clinical qualification","volume":"20","author":"Puntmann","year":"2018","journal-title":"J Cardiovasc Magn Reson"},{"key":"10.1016\/j.diabres.2022.110141_b0090","unstructured":"Berggren K, Hedstrom E, Steding Ehrenborg K, Carlsson M, Engblom H, Ostenfeld E, et al. Multiple convolutional neural networks for robust myocardial segmentation. In proceedings of SSBA. 2020."},{"issue":"7","key":"10.1016\/j.diabres.2022.110141_b0095","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1007\/s00246-022-02894-0","article-title":"Pulse wave velocity measurements by magnetic resonance imaging in neonates and adolescents: methodological aspects and their clinical implications","volume":"43","author":"Lundstr\u00f6m","year":"2022","journal-title":"Pediatr Cardiol"},{"issue":"4","key":"10.1016\/j.diabres.2022.110141_b0100","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1161\/hc0402.102975","article-title":"Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association","volume":"105","author":"Cerqueira","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.diabres.2022.110141_b0105","doi-asserted-by":"crossref","first-page":"108796","DOI":"10.1016\/j.diabres.2021.108796","article-title":"Sodium-glucose transporter inhibition in heart failure: from an unexpected side effect to a novel treatment possibility","volume":"175","author":"Ferrannini","year":"2021","journal-title":"Diabetes Res Clin Pract"},{"issue":"10","key":"10.1016\/j.diabres.2022.110141_b0110","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1007\/s00125-018-4670-7","article-title":"SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review","volume":"61","author":"Verma","year":"2018","journal-title":"Diabetologia"},{"issue":"15","key":"10.1016\/j.diabres.2022.110141_b0115","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.diabres.2022.110141_b0120","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.diabres.2022.110141_b0125","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3109\/10976640009148691","article-title":"Reduction in sample size for studies of remodeling in heart failure by the use of cardiovascular magnetic resonance","volume":"2","author":"Bellenger","year":"2000","journal-title":"J Cardiovasc Magn Reson"},{"issue":"8","key":"10.1016\/j.diabres.2022.110141_b0130","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1111\/imj.14260","article-title":"Effects of empagliflozin treatment on cardiac function and structure in patients with type 2 diabetes: a cardiac magnetic resonance study","volume":"49","author":"Cohen","year":"2019","journal-title":"Intern Med J"},{"issue":"21","key":"10.1016\/j.diabres.2022.110141_b0135","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1161\/CIRCULATIONAHA.119.042375","article-title":"Effect of empagliflozin on left ventricular mass in patients with type 2 diabetes mellitus and coronary artery disease: The EMPA-HEART cardiolink-6 randomized clinical trial","volume":"140","author":"Verma","year":"2019","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.diabres.2022.110141_b0140","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1111\/dom.14363","article-title":"Effects of 6 weeks of treatment with dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on myocardial function and metabolism in patients with type 2 diabetes: A randomized, placebo-controlled, exploratory study","volume":"23","author":"Oldgren","year":"2021","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"10.1016\/j.diabres.2022.110141_b0145","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jacc.2020.11.008","article-title":"Randomized trial of empagliflozin in nondiabetic patients with heart failure and reduced ejection fraction","volume":"77","author":"Santos-Gallego","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.diabres.2022.110141_b0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.dsx.2022.102417","article-title":"Empagliflozin improves quality of life in nondiabetic HFrEF patients. Sub-analysis of the EMPATROPISM trial","volume":"16","author":"Requena-Ibanez","year":"2022","journal-title":"Diabetes Metab Syndr"},{"issue":"8","key":"10.1016\/j.diabres.2022.110141_b0155","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.jchf.2021.04.014","article-title":"Mechanistic insights of empagliflozin in nondiabetic patients with HFrEF: From the EMPA-TROPISM study","volume":"9","author":"Requena-Ib\u00e1\u00f1ez","year":"2021","journal-title":"JACC Heart Fail"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016882272200955X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016882272200955X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:23:39Z","timestamp":1759173819000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016882272200955X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":31,"alternative-id":["S016882272200955X"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2022.110141","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SOdium-glucose CO-transporter inhibition in patients with newly detected Glucose Abnormalities and a recent Myocardial Infarction (SOCOGAMI)","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2022.110141","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"110141"}}